KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Other Non-Current Liabilities (2018 - 2025)

Takeda Pharmaceutical (TAK) has 7 years of Other Non-Current Liabilities data on record, last reported at $230.6 million in Q1 2025.

  • For Q1 2025, Other Non-Current Liabilities rose 137.74% year-over-year to $230.6 million; the TTM value through Mar 2025 reached $230.6 million, up 137.74%, while the annual FY2025 figure was $230.9 million, 131.71% up from the prior year.
  • Other Non-Current Liabilities reached $230.6 million in Q1 2025 per TAK's latest filing, up from $97.0 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $494.3 million in Q1 2023 and bottomed at $97.0 million in Q1 2024.
  • Average Other Non-Current Liabilities over 5 years is $327.4 million, with a median of $366.1 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 80.38% in 2024, then skyrocketed 137.74% in 2025.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $366.1 million in 2021, then rose by 22.7% to $449.2 million in 2022, then grew by 10.06% to $494.3 million in 2023, then tumbled by 80.38% to $97.0 million in 2024, then surged by 137.74% to $230.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Liabilities were $230.6 million in Q1 2025, $97.0 million in Q1 2024, and $494.3 million in Q1 2023.